Massimo Pietropaolo Named McNair Scholar at Baylor
News Oct 29, 2014
The McNair Scholar program at Baylor identifies influential researchers in breast and pancreatic cancer, juvenile diabetes and neuroscience. It is supported by the Robert and Janice McNair Foundation and managed by the McNair Medical Institute. With this funding, Pietropaolo was recruited to Baylor as a professor of medicine in the department of pathology and immunology.
Pietropaolo earned his medical doctorate from the University of Perugia, Italy, and completed a research fellowship at the Joslin Diabetes Center, Harvard Medical School.
As the first scientist to discover the neuroendocrine autoantigen ICA69, a key regulator of the formation and maturation of insulin in pancreatic beta cells, he has made groundbreaking contributions to the adaptive immune responses directed to ICA69 and the islet autoantigen IA-2 to identify subjects who have the greatest risk of developing juvenile diabetes, opening new avenues in the search of ways to prevent the disease .
Currently, Dr. Pietropaolo’s laboratory is in the process of identifying the molecular structure of immunoglobulins s directed to the islet cell molecule IA-2 by targeted mass spectrometry (MS) and barcode sequencing methodologies. This may provide a powerful new tool for understanding autoantibody responses in children with type 1 diabetes and first degree relatives of type 1 diabetic patients undergoing immunologic treatment for type 1 diabetes.
His work has been published in more than 100 peer-reviewed articles. Pietropaolo also has been honored with numerous awards including an Investigator Award from the Association of American Physicians, the Career Development Award from the American Diabetes Association and the Outstanding Alumni Achievement Award from the University of Perugia, School of Medicine, Italy.
Additionally, he serves as chair and reviewer in a number of National Institutes of Health study sections, he is co-director of the Juvenile Diabetes Research Foundation Biomarker Working Group and a standing member of the Type 1 Diabetes Exchange Biobank Scientific Review Committee.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE